Active Ingredient(s): Ambenonium Chloride
FDA Approved: * May 1, 1956
Pharm Company: * SANOFI AVENTIS US
Category: Myasthenic Syndrome

Ambenonium (as ambenonium dichloride, trade name Mytelase) is a cholinesterase inhibitor[1] used in the management of myasthenia gravis. It is classified as reversible.[2] Mechanism of action Ambenonium exerts its actions against myasthenia gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. Myasthenia gravis occurs when the body produces antibodies against acetylcholine receptors, ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.